Thematic ETFs have traditionally focused on technologies or industries, but Defiance ETFs is taking a different approach with the launch of the Defiance Autism Impact ETF (ticker: $ASD), a fund designed to invest in companies supporting autism spectrum disorder and the broader neurodivergent community.

The ETF tracks the VettaFi Autism Impact Index and invests in companies generating significant revenue from products, services, diagnostics, therapies, and research related to autism spectrum disorder and neurodivergence. While the theme itself might be new to investors, Defiance argues that the investment opportunity is rooted in powerful long-term secular trends.

Speaking on The ETF Show, Brendan Cavanaugh, Chief Strategy Officer at Defiance ETFs, explained that the idea for the fund grew from a deeply personal connection.

Defiance founder and CEO Matt Bielski and the firm's Chief Legal Counsel Gabriela Zahn-Bielski have a son diagnosed with autism spectrum disorder, giving the firm firsthand experience navigating therapies, education systems, and support networks available to families affected by ASD.

Though the fund’s origin story might be personal, Cavanaugh says that Defiance is “leading with the investment case,” when it comes to $ASD.

That investment case centers on growing awareness, rising diagnosis rates, expanding public funding, and continued innovation in diagnostics, therapies, education technology, and specialized services. According to Cavanaugh, increasing diagnoses do not necessarily indicate that more individuals have autism, but rather reflect improved awareness, screening, and research.

The fund's index methodology attempts to maintain a pure-play focus. Companies must derive at least 50% of their revenue from autism and neurodivergence-related activities across three primary categories: pharmaceuticals and therapeutics, specialized services and educational technologies, and diagnostics and assessment tools.

As a result, the portfolio extends beyond traditional healthcare companies. Holdings can include educational service providers, therapy-focused businesses, and companies developing tools designed to improve outcomes for neurodivergent individuals.

Defiance believes the opportunity is supported by significant legislative and funding tailwinds. Cavanaugh pointed to continued federal support through the Autism CARES Act, growing insurance coverage mandates across states, and increasing investment in research and treatment development. Despite decades of progress, there are still no FDA-approved medications that directly address the core symptoms of autism spectrum disorder, leaving substantial room for innovation.

What makes $ASD so unique however, is its philanthropic component. Defiance has committed to donating 100% of the fund's net profits to autism-focused nonprofit organizations during the first two years of the fund's life. After that period, at least 50% of net proceeds will continue to be donated.

Still, Cavanaugh emphasized that investors should not view $ASD simply as a charitable vehicle.

"We don't expect people necessarily to just buy this ETF because the cause is near and dear to them," he said. "We expect them to understand that the awareness is creating this broader investment case."

For Defiance, success will ultimately be measured across multiple dimensions: investment performance, growing awareness of autism-related challenges and opportunities, and meaningful charitable impact. But the firm's core message remains clear: ASD is designed to be an investable theme first, with social impact serving as an additional benefit rather than the sole reason to own the fund.

Source: The ETF Show - New Autism-Impact ETF Launched